Lisanne de Koster

373 [18F]FDG-PET/CT: cost-utility analysis alongside an RCT 6 Table 3. Costs and utilities for the Markov Model, including uncertainty. Costs, Base-case value Source Uncertaintya Disutility, Base-case valueb Source Uncertaintya Procedures FDG-PET/CT €754 [476] n.a. Hemithyroidectomy €4,315 [476] ±25% Total / completion thyroidectomy €6,115 [476] ±25% Radioiodine ablation €5,765 [476] ±25% Health states, yearly costs Active surveillance after negative [18F]FDG-PET/CTc €236 [17, 29, 178, 476, 495, 496, 529, 532, 562], expert opinion ±25% 0.02 [29, 176, 495] 0.00-0.05 End of follow-up €0 Expert opinion €0 0.01 Expert opinion 0.00-0.04 Observation after HT for benign nodule 1st year €277 [29, 176, 476, 495, 558, 563] ±25% 0.01 [29, 176, 495, 564] 0.00-0.04 2nd year onwards €0 [29, 176, 563] ±25% 0.01 [29, 176, 495, 564] 0.00-0.04 Observation after HT for malignancy 1st year €529 [176, 467, 476, 563] ±25% 0.03 [29, 176, 495, 564], expert opinion 0.01-0.06 2nd-5th year €252 [176, 467, 476, 563] ±25% 0.02 [29, 176, 495, 564], expert opinion 0.00-0.05 6th year onwards €0 [176, 467, 476, 563] ±25% 0.01 [564] 0.00-0.04 Transient complication due to HT €1,272 [29, 158, 176, 178, 476, 495, 496, 563], EfFECTS ±25% 0.06 [29, 176, 495] 0.02-0.11 Permanent complication due to HT 1st year €5,338 [29, 158, 176, 178, 495, 496, 558, 562, 563], EfFECTS ±25% 0.30 [29] 0.21-0.39 2nd year onwards €825 [29, 158, 176, 495, 562, 563] ±25% 0.30 [29] 0.21-0.39 Hypothyroidism due to HT 1st year €566 [158, 476, 495, 558, 562], EfFECTS ±25% 0.03 [29, 176, 495, 558] 0.01-0.06 2nd year onwards €283 [158, 476, 495, 558, 562] ±25% 0.02 [29, 176, 495, 558] 0.00-0.05 Recurrence of malignancy after HT €1,756 [29, 176] ±25% 0.40 [29] 0.31-0.50 Observation after TT for benign nodule 1st year €843 [29, 158, 176, 476, 495, 558, 562, 563] ±25% 0.06 [29, 176, 495, 558] 0.02-0.11 2nd year onwards €283 [29, 158, 176, 476, 495, 558, 562, 563] ±25% 0.02 [29, 176, 495, 558] 0.00-0.05

RkJQdWJsaXNoZXIy MTk4NDMw